CNSP Valuation
CNS Pharmaceuticals Inc
$
1.060
- Overview
- Forecast
- Valuation
CNSP Relative Valuation
CNSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNSP is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.25
P/B
Median3y
0.23
Median5y
2.37
-564.43
FCF Yield
Median3y
-320.91
Median5y
-208.86
Competitors Valuation Multiple
The average P/S ratio for CNSP's competitors is 0.16, providing a benchmark for relative valuation. CNS Pharmaceuticals Inc Corp (CNSP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
GCO
Genesco Inc
19.480
USD
+0.41%
SIGA
SIGA Technologies Inc
5.430
USD
-1.63%
MTLS
Materialise NV
5.190
USD
+0.97%
EQV
EQV Ventures Acquisition Corp
10.200
USD
+0.20%
PNNT
Pennantpark Investment Corp
6.410
USD
-1.69%
MITK
Mitek Systems Inc
8.100
USD
-2.17%
PACB
Pacific Biosciences of California Inc
1.110
USD
0.00%
CVRX
CVRx Inc
7.290
USD
-0.41%
ESPR
Esperion Therapeutics Inc
0.984
USD
-1.50%
HPP
Hudson Pacific Properties Inc
2.180
USD
+6.34%
FAQ
Is CNS Pharmaceuticals Inc (CNSP) currently overvalued or undervalued?
CNS Pharmaceuticals Inc (CNSP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of CNS Pharmaceuticals Inc (CNSP) is between to according to relative valuation methord.
What is CNS Pharmaceuticals Inc (CNSP) fair value?
How does CNSP's valuation metrics compare to the industry average?
What is the current P/B ratio for CNS Pharmaceuticals Inc (CNSP) as of May 02 2025?
What is the current FCF Yield for CNS Pharmaceuticals Inc (CNSP) as of May 02 2025?
What is the current Forward P/E ratio for CNS Pharmaceuticals Inc (CNSP) as of May 02 2025?